Literature DB >> 29159921

Pharmacokinetic profile of Ceftiofur Hydrochloride Injection in lactating Holstein dairy cows.

J Wang1,2, H Peng1,2, J Kong1,2, T Zhao1,2, S Zhang1,2, X Cao1,2,3.   

Abstract

Ceftiofur (CEF), a broad-spectrum third-generation cephalosporin, exhibits a good activity against a broad range of gram-negative and gram-positive bacteria, including many that produce β-lactamase. To design a rational dosage regimen for the drug in lactating Holstein dairy cows, the pharmacokinetic properties of ceftiofur hydrochloride injection were investigated in six cows after intravenous, intramuscular, and subcutaneous administration of single dose of 2.2 mg/kg BW (body weight). Plasma concentration-time curves and relevant parameters were best described by noncompartmental analysis through WinNonlin 6.3 software. After subcutaneous administration, the absolute bioavailability was 61.12% and the T1/2λz (elimination half-life) was 8.67 ± 0.72 hr. The Cmax (maximum plasma concentration) was 0.88 ± 0.21 μg/ml and Tmax (the time after initial injection to when Cmax occurs) was 1.50 ± 0.55 hr. The MRT (mean residence time) was 11.00 ± 0.30 hr. Following intramuscular administration, the Cmax (1.09 ± 0.21 μg/ml) was achieved at Tmax (1.20 ± 0.26 hr) with an absolute availability of 70.52%. In this study, the detailed pharmacokinetic profiles of free and total CEF showed that this drug is widely distributed and rapidly eliminated and may contribute to a better understanding of the usage of ceftiofur hydrochloride injection in Holstein dairy cows.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Holstein dairy cows; ceftiofur; pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 29159921     DOI: 10.1111/jvp.12469

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  5 in total

1.  Excreted Antibiotics May Be Key to Emergence of Increasingly Efficient Antibiotic Resistance in Food Animal Production.

Authors:  Johannetsy J Avillan; Parvaneh Ahmadvand; Shao-Yeh Lu; Jennifer Horton; Jinxin Liu; Eric Lofgren; Margaret A Davis; ChulHee Kang; Douglas R Call
Journal:  Appl Environ Microbiol       Date:  2022-07-14       Impact factor: 5.005

2.  Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs.

Authors:  Jianzhong Wang; Benjamin K Schneider; Jiao Xue; Pan Sun; Jicheng Qiu; Jonathan P Mochel; Xingyuan Cao
Journal:  Front Vet Sci       Date:  2019-10-17

3.  Kinetics and minimal inhibitory concentrations of ceftiofur in tear film following extended-release parenteral administration (Excede®) in dogs.

Authors:  Anna Catherine Bowden; Rachel A Allbaugh; Joe S Smith; Jonathan P Mochel; Lionel Sebbag
Journal:  Front Vet Sci       Date:  2022-09-20

4.  Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine.

Authors:  Da Sun; Kun Mi; Haihong Hao; Shuyu Xie; Dongmei Chen; Lingli Huang
Journal:  BMC Vet Res       Date:  2020-09-29       Impact factor: 2.741

5.  CD-g-CS nanoparticles for enhanced antibiotic treatment of Staphylococcus xylosus infection.

Authors:  Si-Di Zheng; Zhi-Yun Zhang; Jin-Xin Ma; Qian-Wei Qu; Bello-Onaghise God'spowe; Yue Qin; Xue-Ying Chen; L U Li; Dong-Fang Zhou; Wen-Ya Ding; Yan-Hua Li
Journal:  Microb Biotechnol       Date:  2021-06-28       Impact factor: 5.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.